FDA Affirms Exclusivity Period For Shire ADHD Drug
The U.S. Food and Drug Administration has affirmed its decision to grant a five-year new chemical entity exclusivity period to Shire PLC for its attention deficit hyperactivity disorder drug Vyvanse following...To view the full article, register now.
Already a subscriber? Click here to view full article